Alliance Pharma PLC Notification of Half Year Results (1365X)
26 August 2020 - 4:00PM
UK Regulatory
TIDMAPH
RNS Number : 1365X
Alliance Pharma PLC
26 August 2020
26 August 2020
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Half Year Results,
Analyst Conference Call and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare
group, will announce its results for the six months ended 30 June
2020 on Tuesday 22 September 2020.
A conference call for analysts will be held at 10.30am on 22
September 2020; analysts who require dial-in details, please
contact Buchanan at alliancepharma@buchanan.uk.com .
A recorded webcast of the analyst conference call, including
investor presentation slides, will be made available during the
afternoon of 22 September 2020 at this link:
https://webcasting.buchanan.uk.com/broadcast/5f3fbab0b14d87262643a98b
The recorded webcast will also be made available at the investor
section of Alliance's website,
https://www.alliancepharmaceuticals.com/investors/ .
For more information, please contact Buchanan on 020 7466 5000
or email alliancepharma@buchanan.uk.com .
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Huw Jeremy
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating revenues in more than 100
countries.
We currently own or license the rights to around 90 consumer
healthcare products and pharmaceuticals, which are managed on a
portfolio basis according to their growth potential. Promotional
investment is focused on a small number of brands with significant
international or multi-territory reach. The remainder of the
portfolio comprises products which are sold in a limited number of
local markets and require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSEAFMIESSESA
(END) Dow Jones Newswires
August 26, 2020 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024